Sign up Australia
Proactive Investors - Run By Investors For Investors

New Smith & Nephew boss gives bullish assessment of artificial hip maker’s health

Namal Nawana’s upbeat comments came as Smith & Nephew reported a 4% rise in half-year revenue, confirmed its cost-cutting strategy is progressing well and reiterated full-year guidance
namal nawana, smith and nephew CEO
Nawana took over from Oliver Bohuon in May

New Smith & Nephew PLC (LON:SN.) boss Namal Nawana has given a bullish assessment of the artificial hips and knees maker’s health.

Having had the chance to take a more in-depth look under the bonnet, Nawana, who joined in May, was full of praise for the FTSE 100 group’s products and technology.

READ: Smith & Nephew cuts full-year forecasts after weak Q1

“In my first few weeks at Smith & Nephew I have reviewed our businesses and operations and validated that we have an excellent product portfolio with numerous best-in-class medical technologies,” said the 47-year-old.

“We are now focused on energising and organising the business to accelerate growth.”

Nawana’s upbeat words came as Smith & Nephew reported a 4% rise in first-half revenue to US$2.44bn (H1 17: US$2.34bn). Excluding a small currency gain, underlying revenue rose 2%.

China was one of the standout performers, registering double-digit growth, while the group also reported “improved dynamics” in its hips and knee implants business.

Efficiency drive on track

Operating profits fell to US$372mln (H1 17: US$414mln) as margins dipped 240 basis points to 15.3%, reflecting US$58mln of costs related to the APEX programme – the cost-cutting strategy designed to save the company US$160mln a year by 2022.

Smith & Nephew declared an interim dividend of 14.0 US cents per share, up from 12.3 cents a year earlier.

For the full year, the £12bn company repeated its reduced full-year guidance for underlying revenue growth of between 2-3%, with margins at or above the 19.6% it achieved last year.

Shares leapt 4.5% to 1,380p at the opening bell in London.

View full SN. profile View Profile

Smith & Nephew PLC Timeline

Related Articles

Lung X-Ray
October 08 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use